Evaluation of the bactericidal activity of plazomicin and comparators against multidrug-resistant enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 8, 2018, Pages

  Thwaites, M ^a   Hall, D ^a   Shinabarger, D ^a   Serio, A W ^b   Krause, K M ^b   Marra, A ^a   Pillar, C ^a  

^a Micromyx   (United States)

^b Achaogen   (United States)

Author keywords

Bactericidal; Bactericidal activity; Enterobacteriaceae; Multidrug resistance; Plazomicin

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFTAZIDIME; COLISTIN; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PLAZOMICIN; TIGECYCLINE; 6'-(HYDROXYLETHYL)-1-(HABA)-SISOMICIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; POLYMYXIN; QUINOLONE DERIVATIVE; SISOMICIN; TETRACYCLINE DERIVATIVE;

ARTICLE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; CITROBACTER FREUNDII; DRUG POTENCY; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EVALUATION STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; COMPARATIVE STUDY; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTER; ESCHERICHIA COLI; FLUOROQUINOLONES; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; POLYMYXINS; SISOMICIN; TETRACYCLINES;

EID: 85052018205     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00236-18     Document Type: Article

References (16)

1. Potter RF, D’Souza AW, Dantas G. 2016. The rapid spread of carbapenem-resistant Enterobacteriaceae. Drug Resist Updat 29:30 – 46. https://doi.org/10.1016/j.drup.2016.09.002.
2. Perez F, Endimiani A, Hujer KM, Bonomo RA. 2007. The continuing challenge of ESBLs. Curr Opin Pharmacol 7:459–469. https://doi.org/10.1016/j.coph.2007.08.003.
3. Woodford N, Carattoli A, Karisik E, Underwood A, Ellington MJ, Liv-ermore DM. 2009. Complete nucleotide sequences of plasmids pEK204, pEK499 and pEK516, encoding CTX-M enzymes in three major Escherichia coli lineages from the United Kingdom, all belonging to the international 025:H4-ST131 clone. Antimicrob Agents Chemother 53:4472–4482. https://doi.org/10.1128/AAC.00688-09.
4. Centers for Disease Control and Prevention. 2013. Biggest threats. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/drugresistance/biggest_threats.html.
5. Hawkey P. 2015. Multidrug-resistant Gram-negative bacteria: a product of globalization. J Hosp Infect 89:241–247. https://doi.org/10.1016/j.jhin.2015.01.008.
6. Bremmer DN, Clancy CJ, Press EG, Almaghrabi R, Chen L, Doi Y, Nguyen MH, Shields RK. 2014. KPC-producing Klebsiella pneumoniae strains that harbor AAC(6=)-Ib exhibit intermediate resistance to amikacin. Antimicrob Agents Chemother 58:7597–7600. https://doi.org/10.1128/AAC.03831-14.
7. Ramirez MS, Nikolaidis N, Tolmasky ME. 2013. Rise and dissemination of aminoglycoside resistance: the aac(6=)-Ib paradigm. Frontiers Microbiol 4:121. https://doi.org/10.3389/fmicb.2013.00121.
8. Ramirez MS, Tolmasky ME. 2010. Aminoglycoside-modifying enzymes. Drug Resist Updat 13:151–171. https://doi.org/10.1016/j.drup.2010.08.003.
9. KPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother 63:427–437. https://doi.org/10.1093/jac/dkn547.
10. Hirakata Y, Matsuda J, Miyazaki Y, Kamihira S, Kawakami S, Miyazawa Y, Ono Y, Nakazaki N, Hirata Y, Inoue M, Turnidge JD, Bell JM, Jones RN, Kohno S, SENTRY Asia-Pacific Participants. 2005. Regional variation in the prevalence of extended-spectrum -lactamase-producing clinical isolates in the Asia-Pacific region (SENTRY 1998 –2002). Diagn Microbiol Infect Dis 52:323–329. https://doi.org/10.1016/j.diagmicrobio.2005.04.004.
11. Cox G, Ejim L, Stogios PJ, Koteva K, Bordeleau E, Evdokimova E, Sieron AO, Savchenko A, Serio AW, Krause KM, Wright GD. 19 April 2018. Plazomicin retains antibiotic activity against most aminoglycoside modifying enzymes. ACS Infect Dis https://doi.org/10.1021/acsinfecdis.8b00001.
12. CLSI. 2015. Performance standards for antimicrobial susceptibility testing; 25th informational supplement. CLSI document M100-S25. CLSI, Wayne, PA.
13. CLSI. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard–10th ed. CLSI document M07-A10. CLSI, Wayne, PA.
14. NCCLS. 1999. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. NCCLS document M26-A. NCCLS, Wayne, PA.
15. Sader HS, Fritsche TR, Jones RN. 2009. Potency and bactericidal activity of iclaprim against recent clinical Gram-positive isolates. Antimicrob Agents Chemother 53:2171–2175. https://doi.org/10.1128/AAC.00129-09.
16. Stratton CW. 2003. Dead bugs don’t mutate: susceptibility issues in the emergence of bacterial resistance. Emerg Infect Dis 9:10–16. https://doi.org/10.3201/eid0901.020172.